MiMedx price target lowered to $10 from $12 at Mizuho

Mizuho lowered the firm’s price target on MiMedx (MDXG) to $10 from $12 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices and diagnostics group as part of its 2026 outlook. Despite stock valuations trending back toward two-year highs post the Q3 reports, there is potential for further multiple expansion “under a scenario where the dual AI + Cryptocurrency mega-trades remain influx with Healthcare positioned as the top defensive sector,” the analyst tells investors in a research note.